Clinical Trial Update: A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study with an open-label extension evaluated the safety of oral branaplam (LMI070) in individuals with early manifest Huntington's diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Branaplam (LMI070) (branaplam)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Early Manifest Huntington Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-11-04